Metastatic Liver Cancer
31
9
9
5
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 85/100
16.1%
5 terminated out of 31 trials
50.0%
-36.5% vs benchmark
6%
2 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (31)
68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC)
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
Treat Primary and Metastatic Liver Tumors
T-Cell Therapy (ECT204) in Adults With Advanced HCC
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
Streamlining Radioembolization for CCC and Metastatic Liver Cancer
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures (PANORAMA2)
Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases
Multi-center Clinical Study on the Decision Tree of Precision Hepatectomy in China Precision Hepatectomy Decision Tree
PDO/PDO-TIL/PDOTS for Drug Screen
Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures
Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
Liver Transplantation for Unresectable GIST Liver Metastases
Anti-CEA CAR-T Cells to Treat Colorectal Liver Metastases
Chemotherapy for Resectable Colorectal Liver Metastases
ET1402L1-ARTEMIS™2 T Cells in Alpha Fetoprotein (AFP) Expressing Hepatocellular Carcinoma